Dazostinag, a novel non-CDN STING agonist, has demonstrated potential immune-activating effects in adenoid cystic carcinoma (ACC), a rare and highly lethal malignancy with extremely low response rates to cytotoxic chemotherapy and ICIs. The gene discussed is STING1; the disease is adrenal cortex carcinoma.